Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 8:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 363 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disabilities Multiple Clear all
Completed No phase listed Observational Accepts healthy volunteers

Development of Non-invasive Prenatal Screening Test for Microdeletions Based on Fetal DNA Isolated From Maternal Blood

NCT01852708
View directory record Official record
Conditions
Trisomy 21, Trisomy 18, Trisomy 13, Sex Chromosome Abnormalities, Microdeletion Syndromes
Interventions
Not listed
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,059 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
7
States / cities
San Carlos, California • San Gabriel, California • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 21, 2026, 8:31 AM EDT
Recruiting Phase 2 Interventional

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

NCT07840326
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis, Primary Progressive MS, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive MS (SPMS), Secondary Progressive Multiple Sclerosis (SPMS), Secondary Progressive MS, Non-Active SPMS, Non-Active Secondary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Interventions
SUN-627, Placebo
Drug · Other
Lead sponsor
Sundance Biosciences, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia • Raleigh, North Carolina • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 8:31 AM EDT
Completed No phase listed Observational

Computer Models of Airways in Children and Young Adults With Sleep Apnea and Down Syndrome

NCT01902407
View directory record Official record
Conditions
Down Syndrome, Obstructive Sleep Apnea
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 21, 2026, 8:31 AM EDT
Terminated Phase 2 Interventional Results available

Cannabidiol Oral Solution for the Treatment of Patients With Prader-Willi Syndrome

NCT02844933
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
7
States / cities
Tucson, Arizona • San Diego, California • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 21, 2026, 8:31 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Assess RAD011 (Cannabidiol Oral Solution) for the Treatment of Participants With Prader-Willi Syndrome

NCT05098509
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
RAD011, Placebo
Drug
Lead sponsor
Radius Pharmaceuticals, Inc.
Industry
Eligibility
8 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional

The Impact of an 8-week Supported Exercise Program on Fitness and Symptoms in Adolescents With Down Syndrome

NCT03192540
View directory record Official record
Conditions
Down Syndrome
Interventions
Exercise
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 17 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Research Engagement With People With Intellectual and Developmental Disabilities

NCT04182347
View directory record Official record
Conditions
Intellectual Disability, Developmental Disability, Chronic Conditions, Multiple
Interventions
Health Research ToolKit Development
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional

Proactive Speech and Language Intervention for Infants With Down Syndrome

NCT06450509
View directory record Official record
Conditions
Down Syndrome
Interventions
Babble Boot Camp
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
0 Months to 12 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 21, 2026, 8:31 AM EDT
Recruiting Not applicable Interventional

Delivery of a Culturally Tailored Exercise Training Intervention for Hispanics With Multiple Sclerosis

NCT07606742
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Exercise Training
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Children's Learning Centers Group FNI

NCT03908268
View directory record Official record
Conditions
Relation, Mother-Child, Family Conflict, Emotional Disturbances, Behavior Problem, Development Delay
Interventions
Family Nurture Intervention (FNI), Standard Children's Learning Center (CLC) Program
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
24 Months to 57 Months
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cos Cob, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 21, 2026, 8:31 AM EDT
Completed No phase listed Observational

Non-Invasive Screening for Fetal Aneuploidy: A New Maternal Plasma Marker

NCT00770458
View directory record Official record
Conditions
Down Syndrome (Trisomy 21), Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13), Turner Syndrome
Interventions
Not listed
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
7
States / cities
La Jolla, California • San Diego, California • San Jose, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhance Wellness for Individuals With Long-Term Physical Disabilities

NCT02815878
View directory record Official record
Conditions
Multiple Sclerosis, Muscular Dystrophy, Post-polio Syndrome, Spinal Cord Injury
Interventions
Enhance Wellness
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
45 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 2 Interventional Results available

Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome

NCT02629991
View directory record Official record
Conditions
Prader-Willi Syndrome, Hyperphagia
Interventions
Intranasal Oxytocin (IN-OXT), Matched Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
5 Years to 18 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 1 Interventional

Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers

NCT01401244
View directory record Official record
Conditions
Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature, Healthy
Interventions
somatropin
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 40 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 24, 2017 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome

NCT03440814
View directory record Official record
Conditions
Prader-Willi Syndrome
Interventions
DCCR, Placebo for DCCR
Drug
Lead sponsor
Soleno Therapeutics, Inc.
Industry
Eligibility
4 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Orange, California • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 1 Interventional Results available

Investigation of the Safety of Intranasal Glulisine in Down Syndrome

NCT02432716
View directory record Official record
Conditions
Down Syndrome
Interventions
Insulin glulisine, Saline
Drug
Lead sponsor
HealthPartners Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 6, 2019 · Synced Oct 21, 2026, 8:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Treatment Monitoring in Autism Spectrum Disorder (ASD) in Children

NCT05675371
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Developmental Delay, Autism, Early Infantile, Autism, Infantile
Interventions
Assessment by Expert Clinician During Behavioral Intervention (ABA or similar), Assessment by the EarliPoint Assessment For Autism Spectrum Disorder
Behavioral · Device
Lead sponsor
EarliTec Diagnostics, Inc
Industry
Eligibility
15 Months to 84 Months
Enrollment
325 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
9
States / cities
Phoenix, Arizona • Glendale, California • San Rafael, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

NCT03614663
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel
Drug · Other
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2022 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional

An Accessible and Inclusive Artificial Intelligence Assisted Chronic Disease Self-Management Telehealth Platform

NCT05481593
View directory record Official record
Conditions
Disability Physical, Chronic Condition, Chronic Conditions, Multiple
Interventions
Scheduled Coaching + Gamified Rewards, Scheduled Coaching Calls + Independent Rewards, No Scheduled Coaching Calls + Gamified Rewards, No Scheduled Coaching Calls + Independent rewards
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 21, 2026, 8:31 AM EDT
Completed No phase listed Observational

Characterization of Angelman Syndrome

NCT00296764
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Day to 60 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
6
States / cities
San Diego, California • Boston, Massachusetts • Cincinnati, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Phase 3 Interventional Results available

Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis

NCT00134563
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Teriflunomide, Placebo (for teriflunomide)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,088 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Self-Injurious Behavior in Individuals With Prader-Willi Syndrome

NCT00065923
View directory record Official record
Conditions
Prader-Willi Syndrome, Self-Injurious Behavior
Interventions
Topiramate
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 66 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2002
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 1, 2013 · Synced Oct 21, 2026, 8:31 AM EDT
Not yet recruiting Phase 2 Interventional

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

NCT07812181
View directory record Official record
Conditions
Down Syndrome Regression Disorder (DSRD), Down Syndrome (Trisomy 21), Neuroinflammatory / Neuropsychiatric Disorder
Interventions
Ublituximab
Drug
Lead sponsor
Jonathan Santoro
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 8:31 AM EDT
Completed Not applicable Interventional

Exploring Multiple Self-Help Interventions to Promote Self-Efficacy and Overcome Disability

NCT06646757
View directory record Official record
Conditions
Ulcerative Colitis (UC), Crohn Disease (CD)
Interventions
APP, CBT, HELP, PEER
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 8:31 AM EDT